» Articles » PMID: 32901496

NMR Plasma Metabolomics Study of Patients Overcoming Acute Myocardial Infarction: in the First 12 H After Onset of Chest Pain with Statistical Discrimination Towards Metabolomic Biomarkers

Overview
Journal Physiol Res
Specialty Physiology
Date 2020 Sep 9
PMID 32901496
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Acute myocardial infarction (AMI) is one of the leading causes of death among adults in older age. Understanding mechanisms how organism responds to ischemia is essential for the ischemic patient's prevention and treatment. Despite the great prevalence and incidence only a small number of studies utilize a metabolomic approach to describe AMI condition. Recent studies have shown the impact of metabolites on epigenetic changes, in these studies plasma metabolites were related to neurological outcome of the patients making metabolomic studies increasingly interesting. The aim of this study was to describe metabolomic response of an organism to ischemic stress through the changes in energetic metabolites and aminoacids in blood plasma in patients overcoming acute myocardial infarction. Blood plasma from patients in the first 12 h after onset of chest pain was collected and compared with volunteers without any history of ischemic diseases via NMR spectroscopy. Lowered plasma levels of pyruvate, alanine, glutamine and neurotransmitter precursors tyrosine and tryptophan were found. Further, we observed increased plasma levels of 3-hydroxybutyrate and acetoacetate in balance with decreased level of lipoproteins fraction, suggesting the ongoing ketonic state of an organism. Discriminatory analysis showed very promising performance where compounds: lipoproteins, alanine, pyruvate, glutamine, tryptophan and 3-hydroxybutyrate were of the highest discriminatory power with feasibility of successful statistical discrimination.

Citing Articles

Elevated blood acetoacetate levels reduce major adverse cardiac and cerebrovascular events risk in acute myocardial infarction.

Sato J, Kinoshita K, Sakurai A Open Med (Wars). 2023; 18(1):20230793.

PMID: 37693839 PMC: 10487399. DOI: 10.1515/med-2023-0793.


Investigation of the protective mechanism of leonurine against acute myocardial ischemia by an integrated metabolomics and network pharmacology strategy.

Rong W, Li J, Wang L, Luo S, Liang T, Qian X Front Cardiovasc Med. 2022; 9:969553.

PMID: 36072867 PMC: 9441747. DOI: 10.3389/fcvm.2022.969553.


Research Progress of NMR in Natural Product Quantification.

Wang Z, You Y, Li F, Kong W, Wang S Molecules. 2021; 26(20).

PMID: 34684890 PMC: 8541192. DOI: 10.3390/molecules26206308.


Narrative review of metabolomics in cardiovascular disease.

Muller J, Bertsch T, Volke J, Schmid A, Klingbeil R, Metodiev Y J Thorac Dis. 2021; 13(4):2532-2550.

PMID: 34012599 PMC: 8107570. DOI: 10.21037/jtd-21-22.

References
1.
Ormstad H, Verkerk R, Aass H, Amthor K, Sandvik L . Inflammation-induced catabolism of tryptophan and tyrosine in acute ischemic stroke. J Mol Neurosci. 2013; 51(3):893-902. DOI: 10.1007/s12031-013-0097-2. View

2.
Rehulkova H, rehulka P, Myslivcova Fucikova A, Stulik J, Pudil R . Identification of novel biomarker candidates for hypertrophic cardiomyopathy and other cardiovascular diseases leading to heart failure. Physiol Res. 2016; 65(5):751-762. DOI: 10.33549/physiolres.933253. View

3.
Barberi C, van den Hondel K . The use of cardiac troponin T (cTnT) in the postmortem diagnosis of acute myocardial infarction and sudden cardiac death: A systematic review. Forensic Sci Int. 2018; 292:27-38. DOI: 10.1016/j.forsciint.2018.09.002. View

4.
Khogali S, Pringle S, Weryk B, Rennie M . Is glutamine beneficial in ischemic heart disease?. Nutrition. 2002; 18(2):123-6. DOI: 10.1016/s0899-9007(01)00768-7. View

5.
Xia J, Broadhurst D, Wilson M, Wishart D . Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics. 2013; 9(2):280-299. PMC: 3608878. DOI: 10.1007/s11306-012-0482-9. View